Immuneering Corp
Immuneering Corp (IMRX) is a small-cap biotechnology company focused on discovering and developing therapeutics. As an R&D-led firm with a market capitalisation of about $337.3m, it operates in the developmental stage where scientific progress, regulatory milestones and partnerships tend to drive value. Investors should know this is a high-risk, high-uncertainty profile typical of early-stage biotechs: clinical trial results, regulatory decisions and financing events can cause sharp share-price swings. Financials may be uneven while research programmes advance and the company may need additional capital in the future. That said, the potential upside for successful programmes can be material, which is why some investors allocate a small portion of their portfolio to such names. This summary provides general, educational information only and is not personalised advice. Consider your risk tolerance, investment horizon and the company’s public filings before making decisions.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Immuneering Corp's stock with a target price of $15.2, indicating strong growth potential.
Financial Health
Immuneering Corp is maintaining a solid cash flow and reasonable book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring IMRX
Garage Innovators
Meet the companies that are inventing tomorrow, today. These stocks represent businesses with exceptional in-house research and development, carefully selected by professional analysts for their ability to create breakthrough products and technologies from within.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Research-driven focus
The company’s value depends on scientific and clinical progress; milestones can create upside but outcomes are uncertain.
Catalysts to watch
Clinical readouts, regulatory news and partnerships often drive price moves — though results can be binary and unpredictable.
Small-cap dynamics
With a market cap near $337m, liquidity and financing needs matter; smaller market caps can amplify gains and losses.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
